Ketoalkyd reductoisomerase mutant, genetically engineered bacterium for high yield of D-pantothenic acid and application of genetically engineered bacterium
Through the semi-rational design of enzymes and CRISPR-Cas9 gene editing technology, genetically engineered bacteria with high yield of D-pantothenic acid was constructed, which solved the problem of low yield of D-pantothenic acid synthesis by microbial fermentation and synthesis, and achieved significant improvement in yield and specific transformation of ketone alkyd substrate.
Patent Information
- Application Number
- CN202510347423.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-12-04
- Publication Date
- 2025-06-10
- Estimated Expiration
- 2044-12-04
AI Technical Summary
In the prior art, the yield of D-pantothenic acid synthesis by microbial fermentation is not high, resulting in difficulty in industrial application.
Through the semi-rational design of the enzyme, a ketone alkyd reducing isomerase mutant with substrate specificity was obtained, and a genetically engineered bacteria with high yield of D-pantothenic acid was constructed using CRISPR-Cas9 gene editing technology.
The yield of D-pantothenic acid was increased by about 12.04%, while maintaining a small impact on valine synthesis, achieving specific transformation of ketone alkyd substrate.
Smart Images

Figure CN120118868A_ABST
Abstract
Description
[0001] The present invention is a divisional application of Chinese patent application 202411766945.4, with a filing date of December 4, 2024. The name of the invention of the original application is "Keto-acid reductoisomerase mutant, genetically engineered bacteria with high production of D-pantothenic acid". Technical Field
[0002] The invention belongs to the field of bioengineering, and specifically relates to a ketol-acid reductoisomerase mutant with substrate specificity and its application in constructing a genetic engineering bacterium with high D-pantothenic acid production, a genetic engineering bacterium with high D-pantothenic acid production and a construction method thereof. Background Art
[0003] Pantothenic acid (PA) is an important member of the vitamin B family, also known as vitamin B5 or pantothenic acid, and is an essential vitamin for maintaining normal energy metabolism. Pantothenic acid was first isolated from yeast in 1933 and is widely found in various foods in nature, especially animal liver, vegetables and whole grains. D-pantothenic acid, as a component of coenzyme A (CoA) and acyl carrier protein (ACP), participates in biochemical reactions such as fatty acid synthesis, protein metabolism, and energy metabolism. It has multiple biological functions and is essential for maintaining normal physiological functions. It is widely used in the pharmaceutical industry, food industry, feed processing, cosmetics and other industries.
[0004] Currently, the chemical enzymatic method is the mainstream production method of D-pantothenic acid, which has the advantages of substrate specificity and mild reaction conditions, but has low productivity, high cost, difficulty in industrialization, and the generation of toxic and harmful substances during the production process. Compared with traditional chemical production methods, the products produced by microbial cell factories are more environmentally friendly, reduce pollution to the environment, and meet the urgent needs of modern society for green production. In addition, this production method will reduce carbon emissions to zero or negative values during the production process, thereby reducing the negative impact on the carbon dioxide content in the atmosphere, which is conducive to meeting the challenges of climate change and provides a more environmentally friendly and economically efficient method for producing D-pantothenic acid.
[0005] However, the current chemical enzymatic method for producing D-pantothenic acid still has some drawbacks, such as unstable fermentation process and low yield. Therefore, constructing a strain with higher yield of D-pantothenic acid is still a major challenge. Summary of the invention
[0006] To solve the technical problem of low yield of D-pantothenic acid in microbial fermentation in the prior art, the present invention uses semi-rational design of enzymes to obtain a ketol-acid reductoisomerase mutant with substrate specificity and applies it to the construction of a genetically engineered bacterium with high-yield D-pantothenic acid. The present invention also uses the CRISPR-Cas9 gene editing technology and the ketol-acid reductoisomerase mutant to construct a genetically engineered bacterium with high-yield D-pantothenic acid.
[0007] The technical solution adopted by the present invention is: a ketol-acid reductoisomerase mutant obtained by single mutation at the 47th, 69th, 75th, 115th, and 414th positions of the amino acid sequence shown in SEQ ID NO.1.
[0008] Ketol-acid reductoisomerase (EC 1.1.1.86, AHAIR), also known as acetolactate reductoisomerase, is involved in the biosynthesis of branched-chain amino acids. It is a bifunctional enzyme that can catalyze two distinct reactions at a common active site; it can catalyze two completely different reactions, acting as both an isomerase and a reductase. In the isomerase reaction, 2-acetolactate generates 2,3-dihydroxyisovalerate, an intermediate in the pantothenic acid pathway, through Mg 2+ rearrangement-dependent methyl migration. Therefore, it is one of the key enzymes in the D-pantothenic acid biosynthesis pathway and is encoded by the ilvC gene in Escherichia coli.
[0009] To construct a D-pantothenic acid-producing strain with better performance, the present invention modifies the sites near the interaction between the substrate acetolactate molecule and ketol-acid reductoisomerase to change its substrate promiscuity. Since the active pocket of the enzyme molecule is shallow and the substrate is more likely to bind to the enzyme, ketol-acid reductoisomerase can catalyze the reaction of various 2-keto acids. On the one hand, the present invention selects 6 amino acid sites 68, 75, 110, 132, 155, and 414 near the binding of the substrate and the enzyme as the objects of site-directed mutagenesis. Since alanine has a simple structure and will not significantly change the spatial configuration of the protein, all 7 sites are mutated to alanine. On the other hand, the present invention also selects 4 amino acid sites 47, 69, 43, and 115 that are beneficial to enhancing the affinity of acetolactate as a substrate for ketol-acid reductoisomerase for site-directed mutagenesis respectively. Subsequently, the above mutant is overexpressed in the chassis bacterium with the ilvC gene knocked out through plasmid pACYC, and the better ketol-acid reductoisomerase mutant ilvC A47S 、ilvC K69L 、ilvC K75A 、ilvC V115I 、ilvC S414A and a genetically engineered bacterium with high-yield D-pantothenic acid containing the coding gene of the above better mutant are obtained.
[0010] Preferably, the ketoacid reductoisomerase mutant is obtained by mutating the amino acid sequence shown in SEQ ID NO.1 in one of the following ways:
[0011] (1) Alanine at position 47 is mutated to serine;
[0012] (2) Lysine at position 69 is mutated to leucine;
[0013] (3) Lysine at position 75 is mutated to alanine;
[0014] (4) Valine at position 115 is mutated to isoleucine;
[0015] (5) Serine at position 414 is mutated to alanine.
[0016] The present invention also provides a gene encoding the ketoacid reductoisomerase mutant.
[0017] The present invention also provides a recombinant vector containing the gene encoding the ketoacid reductoisomerase mutant.
[0018] The present invention also provides a genetically engineered bacterium containing the gene encoding the ketoacid reductoisomerase mutant.
[0019] The present invention also provides the application of the ketoacid reductoisomerase mutant in constructing a genetically engineered bacterium with high-yield D-pantothenic acid.
[0020] The present invention also provides a method for constructing a genetically engineered bacterium with high-yield D-pantothenic acid, including: knocking out the ilvC gene in the genome of the chassis bacterium, introducing the gene encoding the ketoacid reductoisomerase mutant into the chassis bacterium and overexpressing it, and constructing a genetically engineered bacterium with high-yield D-pantothenic acid.
[0021] Preferably, the gene encoding the ketoacid reductoisomerase mutant is introduced into the chassis bacterium using the low-copy plasmid pACYC and overexpressed.
[0022] Preferably, the chassis bacterium is Escherichia coli W3110, Trc-panCpanEpanBilvC / ilvG* / ΔavtA / ilvE* / coaA* / ΔilvA / Trc-lpd / Δglk / ilvA* / Trc-pck / Trc-ma eB / Trc-ilvBN / gdhA* T (denoted as DPAL6), which has been disclosed in CN113637618A.
[0023] Preferably, the method for constructing the genetically engineered bacterium with high-yield D-pantothenic acid includes:
[0024] (1) Using the CRISPR-Cas9 gene editing technology, the ilvC gene in the genome of the chassis bacterium DPAL6 was knocked out to obtain the strain DPAL6 / ΔilvC;
[0025] (2) The coding gene of the ketol-acid reductoisomerase mutant was overexpressed in the strain DPAL6 / ΔilvC through the low-copy plasmid pACYC to obtain a genetically engineered bacterium with high yield of D-pantothenic acid.
[0026] The present invention also provides a genetically engineered bacterium with high yield of D-pantothenic acid constructed by the method described above.
[0027] Preferably, the genetically engineered bacterium with high yield of D-pantothenic acid is one of the following:
[0028] (1) Escherichia coli W3110, Trc-panCpanEpanBilvC / ilvG* / ΔavtA / ilvE* / coaA* / ΔilvA / Trc-lpd / Δglk / ilvA* / Trc-pck / Trc-maeB / Trc-ilvBN / gdhA* T / ΔilvC / pACYC-ilvC A47S ;
[0029] (2) Escherichia coli W3110, Trc-panCpanEpanBilvC / ilvG* / ΔavtA / ilvE* / coaA* / ΔilvA / Trc-lpd / Δglk / ilvA* / Trc-pck / Trc-maeB / Trc-ilvBN / gdhA* T / ΔilvC / pACYC-ilvC K69L ;
[0030] (3) Escherichia coli W3110, Trc-panCpanEpanBilvC / ilvG* / ΔavtA / ilvE* / coaA* / ΔilvA / Trc-lpd / Δglk / ilvA* / Trc-pck / Trc-maeB / Trc-ilvBN / gdhA* T / ΔilvC / pACYC-ilvC K75A ;
[0031] (4) Escherichia coli W3110, Trc-panCpanEpanBilvC / ilvG* / ΔavtA / ilvE* / coaA* / ΔilvA / Trc-lpd / Δglk / ilvA* / Trc-pck / Trc-maeB / Trc-ilvBN / gdhA* T / ΔilvC / pACYC-ilvC S414A ;
[0032] (5) Escherichia coli W3110, Trc-panCpanEpanBilvC / ilvG* / ΔavtA / ilvE* / coaA* / ΔilvA / Trc-lpd / Δglk / ilvA* / Trc-pck / Trc-maeB / Trc-ilvBN / gdhA* T / ΔilvC / pACYC-ilvC V115I 。
[0033] The present invention also provides the application of the above-mentioned genetically engineered bacterium with high yield of D-pantothenic acid in the preparation of D-pantothenic acid by microbial fermentation.
[0034] Preferably, the application includes: inoculating the above-mentioned genetically engineered bacterium with high yield of D-pantothenic acid into a fermentation medium containing chloramphenicol resistance, and performing fermentation culture at 37 °C and 100 - 200 rpm until OD 600 = 0.8 - 1.0, then transferring to 30 °C and continuing fermentation at 180 rpm for 48 h. After the fermentation is completed, the supernatant of the fermentation broth is taken and separated and purified to obtain the D-pantothenic acid.
[0035] Among them, the composition of the fermentation medium is preferably as follows: glucose 10 - 30 g / L, ammonium sulfate 10 - 25 g / L, anhydrous betaine 1 - 5 g / L, yeast powder 1 - 5 g / L, potassium dihydrogen phosphate 1 - 5 g / L, anhydrous magnesium sulfate 0.5 - 2 g / L, β-alanine 1 - 5 g / L, 1 - 5 ml / L trace element solution, the solvent is deionized water, and the pH value is natural; the composition of the trace element solution is: 10 g / L CuCl 2 , 10 g / L FeSO 4 ·7H 2 O, 10 g / L ZnSO 4 ·7H 2 O, 0.2 g / L CuSO 4 , 0.02 g / L NiCl 2 ·7H 2 O, and the solvent is deionized water.
[0036] Specifically, the fermentation culture method includes: taking out the genetically engineered bacterial strain with high D-pantothenic acid production that needs to be fermented, streaking it on an LB solid plate, culturing it overnight at 37°C for 12 - 16 h, picking a single colony and inoculating it into an LB test tube, and culturing it at 37°C and 180 rpm for 12 h to obtain a seed solution. Inoculate 1.5 mL of the seed solution into a 250 mL shake flask containing 50 mL of the medium, and culture it on a shaker at 30°C and 180 rpm for 48 h.
[0037] Advantages of the present invention: The present invention uses molecular docking to perform site-directed mutagenesis on ketol-acid reductoisomerase. By enhancing the binding ability between the substrate and the enzyme, the affinity of acetolactate for the substrate is improved, and finally a better ketol-acid reductoisomerase mutant is obtained. Among them, the ketol-acid reductoisomerase mutant ilvC V115I While strengthening the D-pantolactone pathway, it does not affect the synthesis of L-valine; finally, through shake flask fermentation, the D-pantothenic acid production increased by about 12.04%, and compared with the starting strain, the accumulation of valine in the obtained fermentation broth was almost unchanged compared with the control, but the accumulation of the branched-chain amino acid isoleucine was less, achieving the transformation of the substrate specificity of ketol-acid reductoisomerase. Description of the drawings
[0038] Figure 1 Shows the changes in OD600 and D-pantothenic acid titer of DPAL7 (DPAL6 / ΔilvC) in Comparative Example 1 of the present invention.
[0039] Figure 2 Shows the changes in OD600 and D-pantothenic acid titer of DPAL8 (DPAL7 / pACYC-ilvC) in Comparative Example 2 of the present invention.
[0040] Figure 3 Shows the changes in OD600 and D-pantothenic acid titer of DPAL15 (DPAL7 / pACYC-ilvC A47S ) in Example 1 of the present invention.
[0041] Figure 4 Shows the changes in OD600 and D-pantothenic acid titer of DPAL16 (DPAL7 / pACYC-ilvC K69L ) in Example 2 of the present invention.
[0042] Figure 5 Shows the changes in OD600 and D-pantothenic acid titer of DPAL10 (DPAL7 / pACYC-ilvC K75A ) in Example 3 of the present invention.
[0043] Figure 6 Shows the amino acid and D-pantothenic acid titer changes of DPAL18 (DPAL7 / pACYC-ilvC V115I ) in Example 4 of the present invention.
[0044] Figure 7 For the OD600 and D-pantothenic acid titer changes of DPAL14 (DPAL7 / pACYC-ilvC S414A ) in Example 5 of the present invention.
[0045] Figure 8 For the OD600 and D-pantothenic acid titer changes of DPAL9 (DPAL7 / pACYC-ilvC R68A ) in Comparative Example 3 of the present invention.
[0046] Figure 9 For the OD600 and D-pantothenic acid titer changes of DPAL11 (DPAL7 / pACYC-ilvC Q110A ) in Comparative Example 4 of the present invention.
[0047] Figure 10 For the OD600 and D-pantothenic acid titer changes of DPAL12 (DPAL7 / pACYC-ilvC H132A ) in Comparative Example 5 of the present invention.
[0048] Figure 11 For the OD600 and D-pantothenic acid titer changes of DPAL13 (DPAL7 / pACYC-ilvC K155A ) in Comparative Example 6 of the present invention.
[0049] Figure 12 For the OD600 and D-pantothenic acid titer changes of DPAL17 (DPAL7 / pACYC-ilvC V43I ) in Comparative Example 7 of the present invention. Detailed implementation manners
[0050] The following specific embodiments illustrate the implementation manners of the present invention. Those skilled in the art can easily understand other advantages and effects of the present invention from the content disclosed in this specification. The present invention can also be implemented or applied through other different specific implementation manners. Various details in this specification can also be modified or changed based on different viewpoints and applications without departing from the spirit of the present invention. It should be noted that, without conflict, the following embodiments and the features in the embodiments can be combined with each other. In the embodiments of the present invention, unless otherwise specified, the methods used are all conventional methods, and the reagents used can all be obtained from commercial channels.
[0051] In the following embodiments, the final concentration of spectinomycin in the medium is 0.05 mg / L, and the final concentration of kanamycin in the medium is 0.05 mg / L.
[0052] LB medium: 10 g / L peptone, 5 g / L yeast extract, 5 g / L NaCl, with deionized water as the solvent and natural pH value.
[0053] MS medium: 20 g / L glucose, (NH 4 ) 2 SO 4 16 g / L, KH 2 PO 4 2 g / L, MgSO 4 0.5 g / L, 2 g / L yeast extract, CaCO 3 10 g / L, 1 ml / L trace element solution, with deionized water as the solvent and natural pH value; 10 g / L calcium carbonate (sterilized separately); the trace element solution consists of: 10 g / L CuCl 2 、10 g / L FeSO 4 ·7H 2 O, 1 g / L ZnSO 4 ·7H 2 O, 0.20 g / L CuSO 4 、0.02 g / L NiCl 2 ·7H 2 O, with deionized water as the solvent.
[0054] The parental strain E. coli W3110 described in the present invention is from the Coli Genetic Stock Center of Yale University, with a preservation date of August 5, 1975, and a preservation number of CGSC#4474, and has been disclosed in patents US2009 / 0298135A1 and US2010 / 0248311A1.
[0055] HPLC determination of D-pantothenic acid content: Chromatographic conditions: C18 column (250×4.6 mm, particle size 5 μm, Agilent Technologies Co., Santa Clara, CA, USA), detection wavelength: 200 nm, column temperature: 30 °C; sample treatment: dilute the sample with ultrapure water to keep the D-pantothenic acid content between 0.05 g / L and 0.40 g / L; mobile phase: acetonitrile / water / phosphoric acid: (50 / 949 / 1); data acquisition time: 25 min.
[0056] Determination of Amino Acid Content: Analytical Conditions: Hitachi custom ion exchange resin (4.6 mm ID × 60 mm*), Wavelength: 570 nm, 440 nm, Separation Column Temperature: 57 °C; Reaction Column Temperature: 135 °C; Sample Treatment: Dilute the sample with ultrapure water to keep the L-Valine content between 0.05 g / L and 0.4 g / L; Mobile Phase: B1 (700 mL of water / 6.19 g of sodium citrate / 1 M NaOH / 5.66 g of sodium chloride / 19.8 g of citric acid / 135 mL of ethanol); R3 (50 mL of ethanol / 950 mL of water); Data Acquisition Time: 30 min.
[0057] The primer sequence information used in the examples is shown in Table 1.
[0058] Table 1: Primer Sequences
[0059]
[0060] Comparative Example 1: Construction of DPAL7 (DPAL6 / ΔilvC) and Shake Flask Fermentation
[0061] Using DPAL6 as the starting strain, the ilvC gene in the genome was knocked out by CRISPR-Cas9-mediated gene editing technology to subsequently determine the effect of the ketoacid reductoisomerase mutant on the pantothenic acid pathway.
[0062] (1) Construction of pTarget-ΔilvC plasmid: Using the pTarget F plasmid (Addgene Plasmid #62226) as a template, PCR amplification was performed with pT-ΔilvC-F / pT-ΔilvC-R as primers. The PCR product was digested at 37 °C for 3 h with Dpn I; the PCR product of pTarget-ΔilvC was amplified with linearization primers pTarget-XF and pTarget-XR, and the pTarget-ΔilvC linearized vector was recovered and purified by gel electrophoresis for subsequent ligation with Donor DNA.
[0063] (2) Construction of pTD-ΔilvC plasmid: Using the E. coli W3110 genome as a template, the upstream part (F1) of the donor DNA was amplified with ΔilvC-up-F and ΔilvC-up-R as primers, and the downstream part (F2) of the donor DNA was amplified with ΔilvC-down-F and ΔilvC-down-R as primers. F1 and F2 were obtained by recovering and purifying the PCR fragments by gel electrophoresis; according to (One step clone kit, Vazyme Biotech, Nanjing, China) The instruction manual ligates the linearized pTarget-ΔilvC vector, fragment F1, and F2 together, and the pTD-ΔilvC plasmid is obtained through sequencing verification.
[0064] (3) Introduce the pCas plasmid (Addgene Plasmid#62225) into DPAL6, transfer the monoclonal colony to an LB test tube containing 0.05 mg / L kanamycin, and culture overnight at 30 °C; then inoculate it into a 250 mL Erlenmeyer flask containing 50 mL LB medium at an inoculation volume concentration of 1%, and add 500 μl of 1 mol / L L-arabinose, and culture at 150 rpm and 30 °C until OD 600 is 0.4 - 0.6; centrifuge at 4000 rpm and 4 °C for 10 min to collect the cells and prepare electrocompetent cells. The detailed procedure is described in (Molecular Cloning: A Laboratory Manual, 3rd Edition, 99 - 102).
[0065] (4) Use a pipette to aspirate an appropriate amount of pTD-ΔilvC (about 200 ng) plasmid and mix it with the pre-prepared 100 μl electrocompetent cells, and transfer them together into a pre-cooled 2 mm electroporation cuvette. After ice-bathing for about 1 - 2 min, use an electroporator (MicroPluser TM , BIO-RAD) for electroporation transformation. Immediately after the electroporation is completed, add 800 μl of LB medium and immediately aspirate it gently, transfer it to a 2 mL Ep tube, resuscitate at 30 °C for 3 - 4 h, and then spread it on an LB solid plate containing 0.05 mg / L kanamycin and 0.05 mg / L spectinomycin, and culture it upside down at 30 °C for 12 - 16 h. Use ΔilvC-VF / R as primers for colony PCR verification. If a fragment of about 1500 bp can be successfully cloned, it proves to be a positive colony of DPAL7 (DPAL6 derivative, ΔilvC).
[0066] (5) Plasmid elimination: Use an inoculation loop to pick up positive single colonies and inoculate them into LB liquid test tubes containing 1 mM IPTG and 0.05 mg / L kanamycin. Culture at 30°C overnight. The next day, streak the bacterial liquid onto LB solid plates containing 0.05 mg / L kanamycin and culture at 30°C for 24 h. When the bacteria grow to a certain size, pick some single colonies and streak them onto LB plates containing 0.05 mg / L spectinomycin. Single colonies that cannot be streaked onto LB plates containing 0.05 mg / L spectinomycin indicate that their pTarget-ΔilvC plasmid has been successfully eliminated. Then pick up pTarget Single colonies from which the et-ΔilvC plasmid was successfully eliminated were placed in LB test tubes and cultured overnight at 37°C to eliminate the pCas plasmid. The next day, the bacterial liquid was streaked on an LB plate. After culturing at 37°C for 12 hours, some single colonies were picked and streaked on an LB plate containing 0.05 mg / L kanamycin. Single colonies that could not be streaked on the LB plate containing 0.05 mg / L kanamycin had their pCas plasmid successfully eliminated, and ultimately the plasmid-free strain DPAL7 (DPAL6 derivative, ΔilvC) was obtained.
[0067] (6) Shake flask fermentation: DPAL7 (DPAL6 derivative, ΔilvC) and the starting strain DPAL6 as the control group were inoculated into 10 mL of LB medium and cultured at 37°C and 200 rpm as pre-cultures; after 8-12 h, 1 mL of the pre-culture was inoculated into a 500 mL shake flask containing 50 mL of MS medium at a 2% inoculum, and then cultured in a constant temperature shaker at 30°C and 180 rpm for 48 h for strain fermentation; after the fermentation was completed, 1 mL of the fermentation broth was taken to measure the OD 600 At the same time, 1 mL of fermentation liquid was drawn with a pipette and centrifuged at 12000 rpm for 3 min at room temperature. The fermentation supernatant was diluted 5 times and the diluted sample was treated with a water filter membrane to remove impurities. The OD 600 and the D-pantothenic acid content in the fermentation supernatant. Figure 1 shown.
[0068] As can be seen from the figure, the DPA production of the strain with ilvC knocked out in the genome decreased by about 80% compared with DPAL6, indicating that ketol-acid reductoisomerase plays a key role in the DPA production pathway.
[0069] Comparative Example 2: Construction of DPAL8 (DPAL7 / pACYC-ilvC) and shake flask fermentation
[0070] Using DPAL7 as the starting strain, we constructed the recombinant plasmid pACYC-ilvC and transfected it into the chassis strain DPAL7 to verify the effect of ilvC on the titer of D-pantothenic acid.
[0071] (1) Construction of linearized pACYC plasmid vector: Using the original pACYC plasmid as a template, linearize it by using primers pACYC-F and pACYC-R. After verifying the PCR product by nucleic acid gel electrophoresis, digest the residual template with DPNⅠ at 37 °C for 1 h. After digestion, purify the product by clean up and measure the nucleic acid concentration to finally obtain the linearized pACYC vector fragment.
[0072] (2) Amplification of the original ilvC fragment: Using the wild-type E. coli W3110 genome as a template, perform PCR amplification with primers ilvCEc-F and ilvCEc-R. After verifying the product by nucleic acid gel electrophoresis, purify the product by clean up and measure the nucleic acid concentration to finally obtain the amplified ilvC fragment (the nucleotide sequence is shown in SEQ ID NO.2).
[0073] (3) Construction of plasmid pACYC-ilvC: Using the linearized pACYC vector and the amplified ilvC fragment as templates, add the reaction system according to the instructions of the one-step cloning kit (ClonExpress Ultra One Step Cloning Kit). After placing it at 50 °C for 15 min, immediately place it on ice to cool down, and the ilvC gene fragment can be integrated into the multiple cloning site of the pACYC plasmid. Then transform the ligation product into DH5α competent cells. After successful verification by colony PCR, pick the bacteria and transfer them to a test tube to obtain the recombinant plasmid pACYC-ilvC.
[0074] (4) Transform the plasmid pACYC-ilvC into the chassis bacterium DPAL7 to obtain DPAL8. The specific steps refer to step (6) of Comparative Example 1. The OD600 after fermentation of strain DPAL8 and the content of D-pantothenic acid in the supernatant of the fermentation broth are as Figure 2 shown.
[0075] As can be seen from the figure, by constructing the recombinant plasmid pACYC-ilvC to overexpress ilvC, the isomerase activity of DPAL6 was restored compared to the control, and the D-pantothenic acid production was almost the same as that of the control.
[0076] Example 1: Construction and shake flask fermentation of DPAL15 (DPAL7 / pACYC-ilvC A47S )
[0077] Using DPAL7 as the starting strain, use site-directed mutagenesis to mutate the 47th codon gca of the original ilvC in Escherichia coli to agc, so that the encoded amino acid changes from alanine to serine, thereby changing the substrate preference of ketol-acid reductoisomerase.
[0078] (1) Plasmid pACYC-ilvC A47SConstruction: Using plasmid pACYC-ilvC as a template, site-directed mutagenesis was performed on it with primers A47S-F and A47S-R. After verifying the mutated PCR product by nucleic acid gel electrophoresis, the residual template was digested with DPNⅠ at 37°C for 1 h. After digestion, the product was purified by clean up and the nucleic acid concentration was measured. Finally, pACYC-ilvC with ilvC mutation was obtained. A47S Plasmid linearized vector fragment.
[0079] (2) Transform plasmid pACYC-ilvC A47S into the chassis bacterium DPAL7 to obtain DPAL15. The specific steps refer to step (6) of Comparative Example 1. The OD600 after fermentation of strain DPAL15 and the content of D-pantothenic acid in the fermentation broth supernatant are as Figure 3 shown.
[0080] As can be seen from the figure, compared with strain DPAL6, the OD of strain DPAL15 has been greatly improved, and the pantothenic acid yield has increased. This indicates that mutating the 47th codon of ilvC may improve its isomerase activity, resulting in an increase in the D-pantothenic acid yield.
[0081] Example 2: Construction and shake flask fermentation of DPAL16 (DPAL7 / pACYC-ilvC K69L )
[0082] Using DPAL7 as the starting strain, site-directed mutagenesis was used to mutate the original 69th codon aaa of ilvC in Escherichia coli to ctg, so that the encoded amino acid changed from lysine to leucine, in order to change the substrate preference of ketol-acid reductoisomerase.
[0083] Using plasmid pACYC-ilvC as a template, site-directed mutagenesis was performed on it with primers K69L-F and K69L-R to construct plasmid pACYC-ilvC K69L . Transform plasmid pACYC-ilvC K69L into the chassis bacterium DPAL7 to obtain DPAL16. The specific steps refer to Example 1. The OD600 after fermentation of strain DPAL16 and the content of D-pantothenic acid in the fermentation broth supernatant are as Figure 4 shown.
[0084] As can be seen from the figure, compared with strain DPAL6, the OD of strain DPAL16 has been greatly improved, and the pantothenic acid yield has increased. This indicates that mutating the 69th codon of ilvC may improve its isomerase activity, resulting in an increase in the D-pantothenic acid yield.
[0085] Example 3: Construction and shake flask fermentation of DPAL10 (DPAL7 / pACYC-ilvC K75A )
[0086] Using DPAL7 as the starting strain, site-directed mutagenesis was performed to mutate the 75th codon aag of the original ilvC in Escherichia coli to gcg, so that the encoded amino acid changed from lysine to alanine, thereby changing the substrate preference of ketol-acid reductoisomerase.
[0087] Using plasmid pACYC-ilvC as a template, site-directed mutagenesis was carried out on it with primers K75A-F and K75A-R to construct plasmid pACYC-ilvC K75A . Plasmid pACYC-ilvC K75A was transformed into the chassis strain DPAL7 to obtain DPAL10. For the specific steps, refer to Example 1. The OD600 after fermentation of strain DPAL10 and the content of D-pantothenic acid in the supernatant of the fermentation broth are as Figure 5 shown.
[0088] As can be seen from the figure, compared with strain DPAL6, the D-pantothenic acid titer of strain DPAL10 increased slightly. This indicates that mutating the 75th codon of ilvC may increase its isomerase activity, resulting in a slight increase in the yield of D-pantothenic acid.
[0089] Example 4: Construction and shake-flask fermentation of DPAL18 (DPAL7 / pACYC-ilvC V115I )
[0090] Using DPAL7 as the starting strain, site-directed mutagenesis was performed to mutate the 115th codon gtg of the original ilvC in Escherichia coli to att, so that the encoded amino acid changed from valine to isoleucine, thereby changing the substrate preference of ketol-acid reductoisomerase.
[0091] Using plasmid pACYC-ilvC as a template, site-directed mutagenesis was carried out on it with primers V115I-F and V115I-R to construct plasmid pACYC-ilvC V115I . Plasmid pACYC-ilvC V115I was transformed into the chassis strain DPAL7 to obtain DPAL18. For the specific steps, refer to Example 1. The OD600 after fermentation of strain DPAL18 and the content of D-pantothenic acid in the supernatant of the fermentation broth are as Figure 6 shown.
[0092] As can be seen from the figure, by mutating ilvC to construct the recombinant plasmid pACYC-ilvC V115I , compared with strain DPAL6, the yield of D-pantothenic acid increased by about 12.04%. The accumulation of valine hardly changed, but the accumulation of isoleucine decreased by 54.1%. The substrate specificity of ketol-acid was modified, and the D-pantolactone synthesis pathway was strengthened.
[0093] Example 5: Construction and shake flask fermentation of DPAL14 (DPAL7 / pACYC-ilvC S414A )
[0094] Using DPAL7 as the starting strain, site-directed mutagenesis was used to mutate the 414th codon tct of the original ilvC in Escherichia coli to gcg, so that the encoded amino acid was changed from serine to alanine, thereby changing the substrate preference of ketol-acid reductoisomerase.
[0095] Using plasmid pACYC-ilvC as a template, site-directed mutagenesis was carried out on it with primers S414A-F and S414A-R to construct plasmid pACYC-ilvC S414A . Plasmid pACYC-ilvC S414A was transformed into the chassis bacterium DPAL7 to obtain DPAL14. For specific steps, refer to Example 1. The OD600 after fermentation of strain DPAL14 and the content of D-pantothenic acid in the supernatant of the fermentation broth are as Figure 7 shown.
[0096] As can be seen from the figure, compared with strain DPAL6, the OD of strain DPAL14 has been greatly improved, and its yield has also been improved to a certain extent. It is speculated that the enzyme activity may be increased and the pantothenic acid synthesis pathway may be strengthened.
[0097] Comparative Example 3: Construction and shake flask fermentation of DPAL9 (DPAL7 / pACYC-ilvC R68A )
[0098] Using DPAL7 as the starting strain, site-directed mutagenesis was used to mutate the 68th codon cgt of the original ilvC in Escherichia coli to gcg, so that the encoded amino acid was changed from arginine to alanine, thereby changing the substrate preference of ketol-acid reductoisomerase.
[0099] Using plasmid pACYC-ilvC as a template, site-directed mutagenesis was carried out on it with primers R68A-F and R68A-R to construct plasmid pACYC-ilvC R68A . Plasmid pACYC-ilvC R68A was transformed into the chassis bacterium DPAL7 to obtain DPAL9. For specific steps, refer to Example 1. The OD600 after fermentation of strain DPAL9 and the content of D-pantothenic acid in the supernatant of the fermentation broth are as Figure 8 shown.
[0100] As can be seen from the figure, compared with strain DPAL6, the D-pantothenic acid of strain DPAL9 has hardly changed, indicating that mutating the 68th position of ilvC may have little effect on its enzyme activity.
[0101] Comparative Example 4: DPAL11 (DPAL7 / pACYC-ilvCQ110A )Construction and shake flask fermentation
[0102] Using DPAL7 as the starting strain, site-directed mutagenesis was used to mutate the 110th codon cag of the original ilvC in Escherichia coli to gcg, so that the encoded amino acid changed from glutamine to alanine, thereby changing the substrate preference of ketol-acid reductoisomerase.
[0103] Using plasmid pACYC-ilvC as a template, primers Q110A-F and Q110A-R were used for site-directed mutagenesis to construct plasmid pACYC-ilvC Q110A . Plasmid pACYC-ilvC Q110A was transformed into the chassis strain DPAL7 to obtain DPAL11. For the specific steps, refer to Example 1. The OD600 after fermentation of strain DPAL11 and the content of D-pantothenic acid in the supernatant of the fermentation broth are as Figure 9 shown.
[0104] As can be seen from the figure, compared with strain DPAL6, the D-pantothenic acid production of strain DPAL11 decreased, indicating that mutating the 110th codon of ilvC may reduce its isomerase activity, resulting in a decrease in D-pantothenic acid production.
[0105] Comparative Example 5: DPAL12 (DPAL7 / pACYC-ilvC H132A )Construction and shake flask fermentation
[0106] Using DPAL7 as the starting strain, site-directed mutagenesis was used to mutate the 132nd codon cac of the original ilvC in Escherichia coli to gcg, so that the encoded amino acid changed from histidine to alanine, thereby changing the substrate preference of ketol-acid reductoisomerase.
[0107] Using plasmid pACYC-ilvC as a template, primers H132A-F and H132A-R were used for site-directed mutagenesis to construct plasmid pACYC-ilvC H132A . Plasmid pACYC-ilvC H132A was transformed into the chassis strain DPAL7 to obtain DPAL12. For the specific steps, refer to Example 1. The OD600 after fermentation of strain DPAL12 and the content of D-pantothenic acid in the supernatant of the fermentation broth are as Figure 10 shown.
[0108] As can be seen from the figure, compared with strain DPAL6, the OD of strain DPAL12 increased significantly, but the D-pantothenic acid production decreased. It is speculated that mutating the 132nd codon of ilvC may reduce its isomerase activity.
[0109] Comparative Example 6: DPAL13 (DPAL7 / pACYC-ilvCK155A )Construction and shake-flask fermentation
[0110] Using DPAL7 as the starting strain, site-directed mutagenesis was performed to mutate the 155th codon aaa of the original ilvC in Escherichia coli to gcg, so that the encoded amino acid changed from lysine to alanine, thereby changing the substrate preference of ketol-acid reductoisomerase.
[0111] Using plasmid pACYC-ilvC as a template, site-directed mutagenesis was carried out on it with primers K155A-F and K155A-R to construct plasmid pACYC-ilvC K155A . Plasmid pACYC-ilvC K155A was transformed into the chassis strain DPAL7 to obtain DPAL13. For the specific steps, refer to Example 1. The OD600 after fermentation of strain DPAL13 and the content of D-pantothenic acid in the supernatant of the fermentation broth are as Figure 11 shown.
[0112] As can be seen from the figure, compared with strain DPAL6, the OD of strain DPAL13 has been greatly improved, but the isomerase activity has been reduced, resulting in a decrease in the yield of D-pantothenic acid.
[0113] Comparative Example 7: DPAL17 (DPAL7 / pACYC-ilvC V43I )Construction and shake-flask fermentation
[0114] Using DPAL7 as the starting strain, site-directed mutagenesis was performed to mutate the 43rd codon gtc of the original ilvC in Escherichia coli to atc, so that the encoded amino acid changed from valine to isoleucine, thereby changing the substrate preference of ketol-acid reductoisomerase.
[0115] Using plasmid pACYC-ilvC as a template, site-directed mutagenesis was carried out on it with primers V43I-F and V43I-R to construct plasmid pACYC-ilvC V43I . Plasmid pACYC-ilvC V43I was transformed into the chassis strain DPAL7 to obtain DPAL17. For the specific steps, refer to Example 1. The OD600 after fermentation of strain DPAL17 and the content of D-pantothenic acid in the supernatant of the fermentation broth are as Figure 12 shown.
[0116] As can be seen from the figure, compared with strain DPAL6, the OD of strain DPAL17 has been greatly improved, but it is speculated that mutating the 43rd codon of ilvC reduces its isomerase activity, resulting in a decrease in the yield of D-pantothenic acid.
[0117] The embodiments described above are only descriptions of the preferred embodiments of the present invention, and do not limit the scope of the present invention. Without departing from the design spirit of the present invention, various deformations and improvements made by those of ordinary skill in the art to the technical solutions of the present invention shall fall within the protection scope of the present invention.
Claims
1. A keto-acid reductoisomerase mutant, characterized in that: It is obtained by performing a single mutation at position 69 of the amino acid sequence shown in SEQ ID NO.
1.
2. The ketol-acid reductoisomerase mutant according to claim 1, characterized in that The mutation is: the 69th lysine is mutated to leucine.
3. A gene encoding the ketol-acid reductoisomerase mutant according to any one of claims 1 or 2.
4. A recombinant vector containing the gene encoding the ketol-acid reductoisomerase mutant according to claim 3.
5. A genetically engineered bacterium containing the gene encoding the ketol-acid reductoisomerase mutant according to claim 3.
6. Use of the ketol-acid reductoisomerase mutant according to any one of claims 1 or 2 in constructing a genetically engineered bacterium that produces high amounts of D-pantothenic acid.
7. A method for constructing a genetically engineered bacterium that produces high levels of D-pantothenic acid, characterized in that: include: The ilvC gene in the genome of the bottom plate bacteria is knocked out, and the coding gene of the ketol-acid reductoisomerase mutant according to any one of claims 1 or 2 is introduced into the bottom plate bacteria and overexpressed, so as to construct a genetically engineered bacterium with high production of D-pantothenic acid.
8. The method according to claim 7, characterized in that The bottom plate bacteria is Escherichia coli W3110, Trc-panCpanEpanBilvC / ilvG* / ΔavtA / ilvE* / coaA* / ΔilvA / Trc-lpd / Δglk / ilvA* / Trc-pck / Trc-ma eB / Trc-ilvBN / gdhA* T .
9. The genetically engineered bacteria for high production of D-pantothenic acid obtained by the method of claim 7.
10. Use of the genetically engineered bacteria with high D-pantothenic acid production as claimed in claim 9 in the preparation of D-pantothenic acid by microbial fermentation.
Citation Information
Patent Citations
D-pantothenic acid producing strain, construction method and application
CN113637618A
Method for fermentative production of L-methionine
US20090298135A1
Increasing methionine yield
US20100248311A1
Engineering bacteria based on ilv attenuator and application of engineering bacteria to isoleucine production
CN107058323A
High-yield D-pantothenic acid genetically engineered bacterium and construction and application thereof
CN113462630A
Cited By
Ketoalkyd reductoisomerase mutant and genetically engineered bacterium for high yield of D-pantothenic acid
CN120118866A
Ketol-acid reductoisomerase mutant, genetically engineered bacteria with high yield of d-pantothenic acid
CN120118866B
Ketoalkyd reductoisomerase mutant with substrate specificity and construction of D-pantothenic acid high-yield strain
CN120118867A
Construction of ketol-acid reductoisomerase mutants with substrate specificity and d-pantothenic acid high-yield strain
CN120118867B
